InMed Competitors

Stocks . USA . 
Stock . InMed Pharmaceuticals
INM Stock  USD 1.06  0.04  3.64%   
InMed Pharmaceuticals competes with Biodexa Pharmaceticals, Genprex, Biovie, Galmed Pharmaceuticals, and GRI Bio; as well as few others. The company runs under Biotechnology sector within Health Care industry. Analyzing InMed Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of InMed Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out InMed Pharmaceuticals Correlation with its peers.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

InMed Pharmaceuticals vs Kazia Therapeutics Correlation

Modest diversification

The correlation between InMed Pharmaceuticals and KZIA is 0.22 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding InMed Pharmaceuticals and KZIA in the same portfolio, assuming nothing else is changed.

Moving against InMed Stock

  0.53IMMP Immutep Ltd ADRPairCorr
  0.4463E ONWARD MEDICAL BVPairCorr
  0.38KYTX Kyverna TherapeuticsPairCorr
  0.35DSGN Design TherapeuticsPairCorr
  0.31ENGN enGene Holdings CommonPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.051.086.92
Details
Intrinsic
Valuation
LowRealHigh
0.051.056.89
Details
Naive
Forecast
LowNextHigh
0.021.096.93
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.001.121.24
Details

InMed Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between InMed Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of InMed and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of InMed Pharmaceuticals does not affect the price movement of the other competitor.

Risk-Adjusted Indicators

There is a big difference between InMed Stock performing well and InMed Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze InMed Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
BDRX  9.10 (0.90) 0.00 (0.30) 0.00 
 0.00 
 11.45 
(16.09)
 128.35 
GNPX  5.87 (1.11) 0.00 (0.33) 0.00 
 0.00 
 14.98 
(10.23)
 34.02 
BIVI  3.27 (0.53) 0.00  2.65  0.00 
 0.00 
 7.41 
(7.45)
 22.72 
GLMD  4.01 (1.02) 0.00 (1.47) 0.00 
 0.00 
 8.04 
(9.20)
 21.39 
GRI  7.84 (3.75) 0.00  2.18  0.00 
 0.00 
 11.88 
(20.75)
 77.14 
CNSP  3.48 (0.49) 0.00 (0.60) 0.00 
 0.00 
 7.22 
(7.57)
 26.44 
JAGX  7.49 (1.12) 0.00 (0.27) 0.00 
 0.00 
 9.71 
(16.87)
 125.57 
ESLA  6.99 (0.95) 0.00  5.48  0.00 
 0.00 
 12.21 
(15.49)
 50.95 
SILO  3.52 (0.88) 0.00 (0.38) 0.00 
 0.00 
 8.33 
(10.00)
 24.79 
KZIA  7.96  0.02  0.02  0.06  10.17 
(8.53)
 14.69 
(18.36)
 78.79 

InMed Pharmaceuticals Competitive Analysis

The better you understand InMed Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, InMed Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across InMed Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
INM BDRX GNPX BIVI GLMD GRI CNSP JAGX ESLA SILO
 3.64 
 1.06 
InMed
 11.04 
 1.45 
Biodexa
 7.92 
 2.21 
Genprex
 4.03 
 1.19 
Biovie
 4.48 
 0.64 
Galmed
 1.54 
 2.64 
GRI
 2.62 
 5.21 
CNS
 4.92 
 0.58 
Jaguar
 11.11 
 1.04 
Estrella
 3.13 
 0.31 
Silo
Market Volatility
(90 Days Market Risk)
Extremely Dangerous
Somewhat reliable
Dangerous
Unstable
Abnormally volatile
Extremely Dangerous
Slightly risky
Out of control
Very risky
Out of control
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Risky
Risky
Risky
Risky
Risky
Low
Risky
Risky
Risky
Risky
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Under Valued
Over Valued
Under Valued
Over Valued
Fairly Valued
Under Valued
Over Valued
Under Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Hold
Not Available
Buy
Not Available
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Current Ratio
3.52
N/A
10.71
4.5
8.48
5.23
12.34
1.02
N/A
33.28
Net Asset
15.58 M
14.78 M
4.12 M
21.56 M
18.5 M
8.67 M
8.7 M
53.42 M
3.14 M
7.75 M
Profit Margin
-1.71
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
EBITDA
(7.26 M)
(9.08 M)
(21.1 M)
(16.98 M)
(7.42 M)
(11.97 M)
(14.84 M)
(36.66 M)
(8.85 M)
(3.86 M)
Operating Margin
-1.57
N/A
N/A
N/A
N/A
N/A
N/A
-2.35
N/A
-53.47
Current Valuation
(5.61 M)
(3.34 M)
4.55 M
(15.3 M)
(8.96 M)
(2.19 M)
(6.48 M)
33.74 M
39.54 M
(2.06 M)
Price To Book
0.26
0.0929
7.36
0.36
0.19
0.29
0.34
0.92
241.3
0.93
Retained Earnings
(117.24 M)
(150.42 M)
(154.8 M)
(352.14 M)
(200.47 M)
(51.7 M)
(84.42 M)
(346.48 M)
(23.93 M)
(10.87 M)
Current Asset
N/A
N/A
964.42 K
9 K
23.38 M
1.22 B
6.61 M
8.45 M
N/A
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
5.2
N/A
N/A
N/A
N/A
One Year Return
N/A
N/A
N/A
N/A
N/A
12.82
N/A
N/A
N/A
N/A
Beta
0.4
0.99
-0.8
0.52
0.38
-1.25
0.42
0.12
0.52
1.35
Number Of Employees
13
13
13
13
3
3
4
49
N/A
3
Equity Positions Weight
N/A
N/A
N/A
N/A
N/A
99.63
N/A
N/A
N/A
N/A
Shares Outstanding
2.8 M
838.79 K
1.63 M
7.54 M
5.48 M
1.45 M
574.58 K
4.18 M
37.07 M
2.84 M
Three Year Return
N/A
N/A
N/A
N/A
N/A
8.99
N/A
N/A
N/A
N/A
Cash Flow From Operations
(7.77 M)
(12.26 M)
(17.15 M)
(19.03 M)
(5.88 M)
(10.19 M)
(17.11 M)
(29.38 M)
(7.64 M)
(3.22 M)
Total Debt
741.26 K
727 K
2.5 M
349.89 K
2.17 M
71 K
326.07 K
36.53 M
3 M
N/A
Return On Equity
-0.82
-0.62
-6.12
-0.95
-0.46
-2.38
-1.97
-4.12
-2.68
-0.44
Return On Asset
-0.42
-0.39
-2.07
-0.5
-0.21
-1.04
-0.86
-0.38
-1.01
-0.25
Number Of Shares Shorted
122.76 K
19.59 K
483.79 K
153.08 K
61.52 K
700.75 K
28.32 K
552.39 K
864.47 K
61.39 K
Book Value Per Share
2.93
25.25
2.1
3.31
3.49
12.07
17.25
0.85
-0.16
2.13
Current Liabilities
N/A
N/A
587.7 K
961 K
2.54 M
243.82 M
488.66 K
3.91 M
N/A
N/A
Total Asset
15.58 M
14.78 M
4.12 M
21.56 M
18.5 M
8.67 M
8.7 M
53.42 M
3.14 M
7.75 M
Debt To Equity
0.063
N/A
1.11
3.34
0.006
1.23
0.013
N/A
N/A
N/A
Short Ratio
1.02
0.02
0.18
1.38
0.72
0.15
0.43
0.33
0.17
0.46
Target Price
20.0
178.3
7.5
12.0
12.0
644.0
20.0
25.5
16.0
10.0
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
0.51
N/A
N/A
N/A
N/A
Shares Owned By Institutions
15.48
3.64
1.56
3.19
1.05
0.89
12.43
2.24
2.05
5.6
Market Capitalization
2.97 M
1.43 M
6.76 M
11.23 M
3.67 M
4.13 M
3.07 M
2.67 M
81.54 M
5.6 M
Price To Earning
N/A
N/A
-1.09
18.12
-6.79
23.35
-13.7
-0.96
N/A
118.39
Price To Earnings To Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
-0.02
N/A
N/A
Price To Sales
0.62
0.58
N/A
N/A
N/A
N/A
N/A
0.23
N/A
77.69
Net Income
(8.16 M)
(5.73 M)
(21.11 M)
(17.54 M)
(7.52 M)
(11.96 M)
(14.86 M)
(39.03 M)
(8.85 M)
(3.63 M)
Earnings Per Share
-6.09
-27.36
42.5
-12.12
-3.44
-121.8
780.32
-2.58
-0.24
-1.18
Shares Owned By Insiders
0.14
0.95
1.17
3.36
0.91
10.09
0.15
44.48
70.36
6.35
Revenue
4.94 M
N/A
N/A
N/A
N/A
N/A
N/A
11.69 M
N/A
72.1 K
Working Capital
11.03 M
3.78 M
(426.7 K)
18.42 M
13.95 M
5.95 M
6.13 M
12.49 M
4.27 M
6.91 M
Ten Year Return
N/A
N/A
N/A
N/A
N/A
8.79
N/A
N/A
N/A
N/A
Cash And Equivalents
9.35 M
N/A
25.52 M
18.64 M
22.4 M
183.82 M
8.96 M
9.01 M
N/A
8.85 M
Cash Per Share
9.98
N/A
0.53
0.62
0.89
0.3
0.22
0.08
N/A
4.45
Gross Profit
1.62 M
(4.91 M)
N/A
N/A
N/A
N/A
N/A
9.65 M
N/A
66.26 K
Day Typical Price
1.07
1.49
2.27
1.19
0.65
2.55
5.34
0.59
1.07
0.32
Accumulation Distribution
0.0804
526068.0
28818.55
0.12
8461.32
546565.0
861.34
30010.89
6784.21
6864.71
Market Facilitation Index
0.09
N/A
0.0
0.15
0.0
N/A
0.0
N/A
0.0
N/A
Daily Balance Of Power
(0.44)
(0.78)
(0.79)
(0.33)
(0.50)
0.0889
(0.33)
(0.60)
(0.93)
(0.33)
Period Momentum Indicator
(0.04)
(0.18)
(0.19)
(0.05)
(0.03)
0.04
(0.14)
(0.03)
(0.13)
(0.01)
Rate Of Daily Change
0.96
0.89
0.92
0.96
0.96
1.02
0.97
0.95
0.89
0.97
Day Median Price
1.08
1.52
2.3
1.19
0.65
2.51
5.4
0.6
1.09
0.33
Price Action Indicator
(0.04)
(0.15)
(0.19)
(0.02)
(0.03)
0.16
(0.26)
(0.03)
(0.11)
(0.02)
Relative Strength Index
41.13
38.37
41.76
44.12
34.47
27.83
40.19
38.29
37.83
36.72
Coefficient Of Variation
(836.86)
(2,280)
(811.39)
(814.42)
(540.60)
(301.58)
(1,109)
(1,525)
(941.31)
(625.33)
Mean Deviation
4.54
9.1
5.87
3.27
4.01
7.84
3.48
7.49
6.99
3.52
Jensen Alpha
(0.81)
(0.90)
(1.11)
(0.53)
(1.02)
(3.75)
(0.49)
(1.12)
(0.95)
(0.88)
Total Risk Alpha
(1.15)
(2.04)
(1.52)
(0.87)
(1.38)
(4.71)
(0.81)
(1.98)
(1.62)
(1.11)
Sortino Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
5.88
17.2
7.67
4.34
5.27
11.57
4.85
14.11
8.94
4.72
Kurtosis
0.5703
9.84
0.6602
1.59
0.5351
6.67
3.37
24.29
0.7671
0.9888
Potential Upside
7.48
11.45
14.98
7.41
8.04
11.88
7.22
9.71
12.21
8.33
Treynor Ratio
(0.40)
(0.30)
(0.33)
2.65
(1.47)
2.18
(0.60)
(0.27)
5.48
(0.38)
Maximum Drawdown
30.84
128.35
34.02
22.72
21.39
77.14
26.44
125.57
50.95
24.79
Variance
34.52
295.81
58.8
18.86
27.78
133.95
23.57
199.22
79.84
22.28
Market Risk Adjusted Performance
(0.39)
(0.29)
(0.32)
2.66
(1.46)
2.19
(0.59)
(0.26)
5.49
(0.37)
Risk Adjusted Performance
(0.08)
(0.02)
(0.08)
(0.08)
(0.13)
(0.23)
(0.06)
(0.04)
(0.07)
(0.11)
Skewness
(0.26)
1.94
0.9234
0.6975
0.0633
(1.72)
0.7081
3.53
0.0587
0.2363
Semi Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
(0.13)
(0.05)
(0.13)
(0.14)
(0.20)
(0.34)
(0.10)
(0.07)
(0.11)
(0.17)
Value At Risk
(9.30)
(16.09)
(10.23)
(7.45)
(9.20)
(20.75)
(7.57)
(16.87)
(15.49)
(10.00)
Expected Short fall
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

InMed Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of InMed Pharmaceuticals Competition

InMed Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by InMed Pharmaceuticals in relation to its competition. InMed Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of InMed Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact InMed Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to InMed Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your InMed Pharmaceuticals position

In addition to having InMed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Rentals Thematic Idea Now

Rentals
Rentals Theme
Companies providing rental and leasing services to public and business. The Rentals theme has 36 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Rentals Theme or any other thematic opportunities.
View All  Next Launch
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
How To Invest In InMed
Details
Is InMed Stock a good investment?
Details
What is InMed Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out InMed Pharmaceuticals Correlation with its peers.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value - what InMed Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY